Comparative Study of Hydroxychloroquine and Ivermectin in COVID-19 Prophylaxis

Last updated: October 5, 2020
Sponsor: Nucleo De Pesquisa E Desenvolvimento De Medicamentos Da Universidade Federal Do Ceara
Overall Status: Active - Recruiting

Phase

N/A

Condition

N/A

Treatment

N/A

Clinical Study ID

NCT04384458
HCQ+IVM
  • Ages 18-70
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

We have to be aware of the challenge and concerns brought by 2019-nCoV to our healthcare workers. Front-line healthcare workers can become infected in the management of patients with COVID-19; the high viral load in the atmosphere, and infected medical equipment are sources for the spread of SARS-CoV-2. If prevention and control measures are not in place, these healthcare workers are at great risk of infection and become the inadvertent carriers to patients who are in hospital for other diseases. Nowadays a question that has not yet been clarified by science has been arises: is hydroxychloroquine associated with zinc compared to ivermectin associated with zinc effective as a prophylaxis for asymptomatic professionals involved in the treatment of suspected or confirmed case of COVID-19?

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Aged 18 - 70 years;

  • Professionals working in areas of high exposure and high risk of transmission ofSARS-COV-2;

  • Understands and agrees to comply with planned study procedures;

  • Signed informed consent for participation in the study.

Exclusion

Exclusion Criteria:

  • Pregnancy or breastfeeding;

  • Major allergy to Hidroxychloroquine, chloroquine or 4-aminoquinolines;

  • Serum potassium lower than 3.4 mEq/l;

  • Serum magnesium lower than 1.7 mg/dL;

  • QTc interval > 470 ms for man and > 480 ms for woman;

  • Weight < 40 kg;

Study Design

Total Participants: 400
Study Start date:
July 20, 2020
Estimated Completion Date:
April 30, 2021

Study Description

The study is a open-blind, randomised trial that will be conducted in asymptomatic professionals working in areas of high exposure and high risk of transmission of SARS-COV-2.

After obtaining fully informed consent, the investigator will recruit workers in areas of high exposure and high risk of transmission of SARS-COV-2.

Participants will be divided into 2 groups:

  • Hydroxychloroquine (HCQ) = 400mg twice on day 1, 400mg/day on day 2, 3, 4, and 5 followed by 400mg once every 05 days, for the next 7 weeks associated with 20 milligrams twice on day of active zinc for 45 consecutive days;

  • Ivermectin (IVM) = Dosage guidelines based on participant body weight, once on day for 2 consecutive days, This dose schedule should be repeated every 14 days for 45 days associated with 20 milligrams twice on day of active zinc.

Connect with a study center

  • Drug Research and Development Center (NPDM), Federal University of Ceará (UFC)

    Fortaleza, Ceará 60430-275
    Brazil

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.